Head and neck squamous cell carcinomas (HNSCC) contain a small subpopulation of stem cells endowed with unique capacity to generate tumors. These cancer stem cells (CSC) are localized in perivascular niches and rely on crosstalk with endothelial cells for survival and self-renewal, but the mechanisms involved are unknown. Here, we report that stromal interleukin (IL)26 defines the tumorigenic capacity of CSC sorted from primary human HNSCC and transplanted into mice.
INTRODUCTION
Head and neck squamous cell carcinomas (HNSCC) contain a small population of highly tumorigenic cells that exhibit self-renewal and multipotency, hallmarks of stem cells [1, 2] . Emerging evidence from HNSCC and other tumor types suggests that cancer stem cells (CSC) exhibit resistance to chemotherapy and radiotherapy and might be involved in the establishment of metastasis, which is a major cause of cancer-related deaths [3] [4] [5] . Such findings led to the hypothesis that improvements in the long-term outcome of patients with cancer will require ablation of CSC. CSC and physiological stem cells share similar characteristics, such as differentiation and selfrenewal [6, 7] . Therefore, direct targeting of CSC might be accompanied by toxicities related to the unintended elimination of normal stem cells (e.g., hematopoietic stem cells). We recently demonstrated that CSC reside in perivascular niches in patients with HNSCC, and that endothelial cells contribute to the survival and self-renewal of CSC [8] . Importantly, CSC depend on crosstalk with tumor-associated endothelial cells for their survival and maintenance of an undifferentiated state [8] , which may also contribute to tumor dormancy [9] . These discoveries raise the exciting possibility that cancer patients may benefit from the therapeutic blockade of the crosstalk between endothelial cells and CSC within the perivascular niche.
Both, physiological and CSC, depend on their microenvironment for survival and proliferation [6, 7, 10] . The protective function of the crosstalk among cells within the perivascular niche has been identified in neural stem cells [11] and neural tumors [12] . The observation that CSC reside in perivascular niches in HNSCC [8] suggests that potent antiangiogenic drugs may have a therapeutic effect on both, the endothelial cells and the CSC. However, emerging evidence demonstrated that certain antiangiogenic therapies might lead to the development of evasive resistance by enhancing the invasive phenotype of tumor cells [13] [14] [15] . These studies suggest that patients may benefit from a targeted approach that blocks signaling pathways initiated by endothelial cells and that contribute to CSC survival and selfrenewal. However, the mechanisms involving the crosstalk between endothelial cells and CSC are unknown, leaving these targets unidentified.
Independent studies have shown a strong correlation between high serum Interleukin-6 (IL-6) levels and poor survival of patients with head and neck cancer [16, 17] . These studies have proposed the use of serum IL-6 as a biomarker to predict tumor recurrence and patient survival. IL-6 activates its downstream target signal transducer and activator of transcription 3 (STAT3), which is constitutively active in several malignancies including those of the head and neck [18] . Indeed, therapeutic inhibition of STAT3 has been found to slow down tumor growth [19, 20] . Interestingly, IL-6 plays a critical role in the biology of CSC in breast and brain tumors [21] [22] [23] . It is known that endothelial cells secrete high levels of IL-6, especially in response to inflammatory stimuli [24] , which play a major role in the pathobiology of most epithelial cancers. It has also been shown that the IL-6 receptors (IL-6R, gp130) exhibit aberrant expression patterns in some CSC, such as gliomas [22] . However, the role of IL-6 signaling in the crosstalk between endothelial cells and CSC remains unknown.
Here, we unveiled a paracrine signaling pathway initiated by IL-6 secreted by endothelial cells that enhances the survival, self-renewal, and tumorigenic potential of primary human head and neck cancer stem-like cells. Using laser capture microdissection (LCM), we determined that IL-6 expression is higher in the endothelial cells than in the tumor cells of primary human HNSCC, providing strong clinical rationale for this study. Notably, we observed that endothelial cell-secreted IL-6 enhances the tumorigenic potential and the survival of cancer stem-like cells using a series of complementary approaches that included transplantation of primary human head and neck cancer stemlike cells ( HIGH cells with an anti-IL-6R antibody (tocilizumab). Collectively, these data demonstrate that endothelial IL-6 contributes to the biology of CSC and suggest that therapeutic inhibition of this pathway would be beneficial for patients with head and neck cancer.
MATERIALS AND METHODS

Head and Neck Cancer Stem-Like Cell Sorting
The use of primary human tumor specimens was done under protocols approved by the University of Michigan Institutional Review Board. Tumors were cut and minced with a sterile scalpel until they could pass through a 25 ml pipette tip. They were mixed in a 9:1 solution of Dulbecco's modified Eagle's medium (DMEM)-F-12 (Hyclone, Waltham, MA. www.thermoscientific.com) and Collagenase/Hyaluronidase (Stem Cell Technologies, Vancouver, BC, Canada. www.stemcell.com). This mixture was then incubated at 37 C for 1 hour and passed through a 10-ml pipette every 15 minutes for mechanical dissociation. Cells were filtered through a 40-mm nylon sieve (BD Falcon, BD Biosciences, Franklin Lakes, NJ. www.bdbiosciences. com), washed with low glucose DMEM, and centrifuged at 800 rpm for 3 minutes. Single-cell suspensions obtained from primary specimens (as well as from cell lines or xenografts) were washed, counted, and resuspended at 1 3 10 6 cells per milliliter PBS. The Aldefluor kit (Stem Cell Technologies, Vancouver, BC, Canada.) was used to identify cells with high ALDH activity. Briefly, cells were suspended in activated Aldefluor substrate BODIPY-aminoacetate (BAA) or in a specific ALDH inhibitor diethylaminobenzaldehyde (DEAB) for 45 minutes at 37 C. Then, cells were exposed to anti-CD44 (clone G44-26BD; Pharmingen, BD Biosciences, Franklin Lakes, NJ). A series of lineage markers (i.e., anti-CD2, CD3, CD10, CD16, CD18, and CD31; BD Pharmingen) was used to eliminate lineage cells, mouse cells were eliminated using anti-H2K d antibody (BD Biosciences, Franklin Lakes, NJ. www.bdbiosciences.com), and 7-Aminoactinomycin (BD Pharmingen) was used to eliminate nonviable cells. Here and throughout this manuscript, in vitro studies were done in at least triplicate specimens per condition, and three independent experiments were performed to verify reproducibility of the data.
Orosphere Assay
Nonadherent spheroids of head and neck cancer cells (named orospheres) were generated from fluorescence-activated cellsorted cells (5 3 10 3 cells/well) cultured in triplicate wells in ultra-low attachment plates (Corning, NY. www.corning.com), as we showed [25] . Briefly, cells were cultured in low glucose DMEM containing or not 24-hour conditioned medium (CM) from primary human dermal microvascular endothelial cells (HDMEC, Lonza, Indianapolis, Indiana. www.lonza.com) collected in serum-free endothelial basal medium (Lonza) at a ratio of 3:1. Alternatively, cells were treated with HDMEC CM containing 0.4 mg/ml anti-IL-6 antibody (R&D Systems, Minneapolis, MN. www.rndsystems.com), 10 mg/ml humanized anti-IL-6R antibody (Tocilizumab, Chugai Pharmaceuticals, Tokyo, Japan. www. chugai-pharm.co.jp), or nonspecific isotype-matched IgG. As a positive control, we used 20 ng/ml rhIL-6 (R&D Systems). After 3 days, orospheres (defined as colonies of 25 cells) were visualized and quantified under light microscopy.
Severe Combined Immunodeficient Mouse Model of Human Tumor Angiogenesis
Xenograft tumors vascularized with functional human microvessels were generated in severe combined immunodeficient (SCID) mice (CB17 SCID; Taconic, Hudson, NY. www.taconic.com), as we described [26] . Briefly, 0-1,000 head and neck cancer stem-like cells (ALDH LOW cells. Starting on Day 1, mice received weekly intraperitoneal injections of either 10 mg/kg humanized anti-IL-6R antibody (Chugai Pharmaceuticals) or nonspecific IgG, as described [27] . After 30 days, mice were euthanized and tumors were retrieved, measured, weighed, and processed. The impact of host IL-6 on tumor initiation was evaluated in C57B6 IL-62/2 and IL-61/1 mice [28] originally purchased from the Jackson Laboratories, and backcrossed onto an immunodeficient/athymic mouse background.
RESULTS
Stromal IL-6 Enhances the Survival of Cancer Stem-Like Cells
Serum IL-6 has been identified as an independent predictor of poor survival in head and neck squamous cell carcinoma patients [17] . It is known that IL-6 is a potent inflammatory cytokine secreted by stromal cells, and that IL-6 enhances stem cell properties in gliomas [22] . However, the mechanisms underlying the effect of endothelial cell-secreted IL-6 2846 Endothelial IL-6 and Cancer Stem Cells V C AlphaMed Press 2014 on the biology of HNSCC are unknown. To begin to understand the impact of stromal IL-6 on the survival of CSC, we generated tumor xenografts by transplanting primary human cancer stem-like cells in IL-62/2 athymic mice (Fig. 1A) . For this, immediately after surgical removal of the primary tumor from patients with HNSCC (Supporting Information Fig. S1 (Fig. 1C ). These data demonstrate that stromal IL-6 plays a critical role in the head and neck tumor microenvironment, and contributes CSC survival, tumor initiation, and growth. Considering our recent observation that CSC reside in the perivascular niche in HNSCC [8] , and the demonstration that endothelial cells challenged by mediators of inflammation secrete high levels of IL-6 [24] , we explored the possibility that tumor-associated endothelial cells constitute an important source of IL-6 within the perivascular CSC niche. To quantify the relative expression of IL-6 in different microenvironmental compartments in human HNSCC, we performed LCM of endothelial cells or carcinoma cells from several head and neck cancer patients [29] and observed that IL-6 expression was significantly higher in the endothelial cells than in the tumor cells (Fig. 1D ). These data were corroborated by the observation that human endothelial cells secrete more IL-6 than HNSCC cell lines (p < .05) (Supporting Information Fig.  S2A , S2B). Confocal microscopy from human HNSCC tissue sections revealed colocalization of ALDH and IL-6R (Fig. 1E) Fig. 2A-2D ). Time to palpability was used as a determinant of the tumorigenic potential of the cell combinations tested here. We observed that transplantation of 1,000 ALDH-HIGH CD44
HIGH cells generated tumors in 100% of the mice (n 5 26) within 38 days (Fig. 2B ). However, cotransplantation of HDMEC-shRNA-IL-6 with ALDH HIGH CD44 HIGH significantly delayed (p 5 .0016) the time to tumor palpability as compared to cotransplantation of scrambled sequence control endothelial cells and ALDH HIGH CD44 HIGH (Fig. 2B ). When individual tumors are tracked, one observes an overall trend for earlier initiation and larger volumes of tumors vascularized with HDMEC-shRNA-C than in tumors vascularized with HDMEC-shRNA-IL-6 cells (Fig. 2C) . Notably, the average volume was smaller when endothelial cells stably transduced with shRNA-IL-6 were used to vascularize the xenograft tumors generated with cancer stem-like cells sorted from three different patients, demonstrating that this effect was not patient-specific (Fig. 2D ).
To more rigorously study the effect of endothelial cellsecreted IL-6 on tumor initiation, we performed a serial dilution experiment. We implanted 1,000, 100, 10, or 0 ALDH-HIGH CD44
HIGH cells sorted from a primary human HNSCC along with either HDMEC-shRNA-C or HDMEC-shRNA-IL-6 cells. We observed that cotransplantation of HDMEC-shRNA-IL-6 with ALDH HIGH CD44 HIGH significantly delayed (p 5 .0004) tumor initiation as compared to cotransplantation of control endothelial cells and ALDH HIGH CD44 HIGH ( Fig. 2E ), confirming the data discussed above (Fig. 2B) . Notably, all implants containing at least 10 ALDH HIGH CD44 HIGH cells generated tumors (Fig. 2F) .
However, the larger the number of cancer stem-like cells, the shorter the time to palpability (Fig. 2F) . A pair-wise statistical comparison between different ALDH HIGH CD44 HIGH cell densities demonstrated that the greater the initial number of cancer stem-like cells, the greater the effect of endothelial cellsecreted IL-6 in promoting tumors (Fig. 2G) . Together, these studies demonstrate that endothelial cell-secreted IL-6 enhances the tumorigenic potential of cancer stem-like cells in vivo.
The density (fraction) of CSC in a tumor is considered indicative of poor prognosis for cancer patients [30] . To evaluate the effects of endothelial cell-secreted IL-6 on the fraction of cancer stem-like cells in vivo, we evaluated the percentage of ALDH HIGH CD44 HIGH cells in xenograft tumors generated with cancer stem-like cells retrieved from primary human HNSCC ( Fig. 2A) . Ablation of endothelial cell-secreted IL-6 within the tumor microenvironment resulted in a significant decrease in the proportion of cancer stem-like cells (p 5 .041), as compared to xenografts vascularized with control endothelial cells from cancer stem-like cells from primary patients (Fig. 3A) . To confirm the studies performed with cells sorted from primary human HNSCC, we repeated these analyses with cells sorted from a well-characterized human HNSCC cell line (UM-SCC-74A). We observed that the fraction of cancer stem-like cells was significantly reduced (p 5 .010) and the tumor initiation in xenografts was delayed (p 5 .0008) when xenografts were vascularized with IL-6-silenced human endothelial cells (Fig.  3B, 3C) . Notably, the tumor microvascular density was not affected by the silencing of IL-6 in the endothelial cells, as determined by sorting these xenograft tumors for the endothelial marker CD31 (Supporting Information Fig. S2D ).
Endothelial Cell-Secreted IL-6 Promotes CSC Properties In Vitro
To evaluate the functional role of endothelial cell-secreted IL-6 on cancer stem-like cells in vitro, we exposed unsorted head and neck cancer cells (UM-SCC-74A) to endothelial cell CM in presence of a neutralizing antibody to IL-6 and measured the percentage of ALDH HIGH CD44 HIGH by flow cytometry (Fig. 3D) . Endothelial cell CM increased the fraction of cancer stem-like cells (Fig. 3D, 3E ). However, treatment of the CM with anti-IL-6 antibody reduced the percentage of cancer stem-like cells back to baseline levels (Fig. 3E) , without a significant effect in overall cell survival (data not shown). To evaluate the effect of endothelial cell-secreted IL-6 on the LOW cells, and the number of orospheres was increased upon treatment with endothelial cell CM ( Fig.  3F; Supporting Information Fig. S3 ), confirming our previous report [8] . Notably, neutralizing anti-IL-6 antibody inhibited the inductive effect of endothelial cell CM, while rhIL-6 increased the number of orospheres (but not to the same extent as the CM). To ascertain that the orospheres were not formed simply by cell aggregation, we also performed singlecell colony formation assays in ultra-low attachment plates (Fig. 3G) . We observed that endothelial cell CM increased the number of orospheres as compared to controls, and that an anti-IL-6 neutralizing antibody blocked this effect.
To verify the data obtained with anti-IL-6 antibody, we used a second approach consisted of treating unsorted tumor cells with CM from the HDMEC-shRNA-IL-6 or HDMEC-C cells 2850 Endothelial IL-6 and Cancer Stem Cells V C AlphaMed Press 2014 (Fig. 3H) . A more potent induction of the CSC fraction upon treatment with CM from HDMEC-shRNA-C than with HDMECshRNA-IL-6 CM was observed (Fig. 3H, 3I) . Importantly, silencing of IL-6 in the endothelial cells abrogated endothelial cell CM-induced orosphere formation (Fig. 3J) . And adding recombinant human IL-6 was sufficient to rescue the effect of IL-6-depleted conditioned-media on orosphere formation (Fig.  3J) .
It has been postulated that CSC exhibit an invasive phenotype, which could be involved in the generation of secondary tumors [31] . Considering the fact that human HNSCC are highly invasive, we evaluated the effects of endothelial cellsecreted IL-6 on the invasive phenotype of ALDH HIGH CD44 HIGH cells in vitro. We observed that CM from endothelial cells significantly enhanced the invasive potential of ALDH HIGH CD44-HIGH cells (Supporting Information Fig. S4A, S4B) . Notably, treatment with neutralizing antibody against IL-6, or exposure to HDMEC-shRNA-IL-6 CM, abrogated the inductive effect of the endothelial cell CM (Supporting Information Fig. S4 ). Taken together, these findings demonstrate that endothelial cells constitute a critical source of the IL-6 that promotes the survival, self-renewal, and invasive potential of head and neck cancer stem-like cells in vitro.
Endothelial Cell-Secreted IL-6 Induces STAT3 Phosphorylation in CSC
The canonical IL-6 signal transduction pathway involves binding to IL-6R and to the common signal transducing receptor gp130, signaling through the Janus kinases, and activation of STAT3. Activation of STAT3 signaling plays an important role in the self-renewal and stemness of embryonic stem cells, intestinal stem cells, and glioblastoma stem cells [23, [32] [33] [34] . Therefore, phosphorylation of STAT3 might be considered indicative of stemness. Immunohistochemical examination of primary HNSCC tissues showed strong expression of p-STAT3 around tumor blood vessels (Fig. 4A) LOW cells exhibited constitutive activation of this pathway (Fig. 4B) . Parallel experiments with a head and neck cancer cell line (UM-SCC-74A) also confirmed there was significant expression of P-STAT3 with cells sorted from primary HNSCC (Fig. 4B) .
To evaluate the impact of endothelial cell-secreted factors on the activation of STAT3, we exposed ALDH HIGH CD44 HIGH cells to endothelial cell CM and analyzed the phosphorylation levels of STAT3 over time. We found that endothelial cell CM enhanced STAT3 phosphorylation in ALDH HIGH CD44 HIGH cells in a time-dependent manner (Fig. 4C) . Blockade of IL-6 with neutralizing antibodies abrogated the inductive effect of endothelial cells on STAT3 phosphorylation (Fig. 4D) . Likewise, exposure of cancer stem-like cells to CM from IL-6-silenced endothelial cells did not induce STAT3 phosphorylation beyond baseline levels (Fig. 4E) . Notably, knockdown STAT3 in ALDH HIGH CD44-HIGH cells (Fig. 4F ) prevented rhIL-6-induced increase in the number of orospheres (Fig. 4I) . And silencing of IL-6R (Fig. 4F ) inhibited baseline levels of STAT3 phosphorylation, and partially inhibited endothelial cell CM-induced P-STAT3 (Fig. 4G) . The number of orospheres induced by endothelial cell CM was also smaller in IL-6R-silenced tumor cells, as compared to controls (Fig. 4H) . Collectively, these data demonstrated that IL-6 secreted by endothelial cells signals through IL-6R to activate STAT3 signaling, which functions as a critical regulator of the self-renewal and survival of head and neck CSC.
Humanized Anti-IL-6R Antibody Inhibits the Survival of Cancer Stem-Like Cells and Delays Tumor Initiation
To enhance the translational significance of this work, we performed a series of experiments with the humanized antihuman IL-6R antibody tocilizumab developed by Chugai/Roche [27] . This antibody was approved by the FDA for the treatment of rheumatoid arthritis in 2010. Tocilizumab blocked the effect of endothelial cell CM on the generation of orospheres with cells sorted from primary HNSCC (Fig. 5A ) and inhibited endothelial cell-induced phosphorylation of STAT3 in vitro (Fig. 5B) ( Fig. 5C ). No significant weight reduction was observed in mice treated with tocilizumab during the course of this experiment, suggesting that this drug was well tolerated (Supporting Information Fig. S5 ). While all mice transplanted with 1,000 ALDH-HIGH CD44 HIGH cells developed tumors in the IgG control group (6/6), only one tumor (1/6) was created in the tocilizumab group (Fig. 5D) . As expected, none of the mice (0/12) transplanted with control ALDH LOW CD44
LOW cells developed tumors within the experimental time (Fig. 5D) . The average tumor volume of the mice in the IgG group was significantly higher than in the tocilizumab-treated group (Fig. 5E) . Importantly, we observed a significant reduction in the proportion of CSC (ALDH   HIGH   CD44 HIGH cells) in mice treated with tocilizumab, as compared to mice from the IgG control group (Fig. 5F ).
To more fully understand the effect of the anti-IL-6R antibody tocilizumab on the fraction of CSC, we performed a long-term in vivo of 4 months (Fig. 5G) . In this case, we generated xenograft tumors with ALDH HIGH CD44
HIGH cells sorted from UM-SCC-74B and administered weekly anti-IL-6R antibody for 16 weeks or for 4 weeks followed by 12 weeks without antibody. We observed that treatment with the anti-IL-6R antibody resulted in a smaller fraction of ALDH HIGH CD44
HIGH cells in this tumor model. Surprisingly, this effect was maintained in the group without antibody for the last 12 weeks, suggesting that the effect of IL-6 signaling blockade on head and neck CSC is long lasting.
DISCUSSION
Acquired resistance to therapy is a major challenge in the management of patients with head and neck cancer. Platinumbased drugs have substantially improved the control of localregional disease [37] . However, with improved local control of the disease with enhanced radiation therapy, concurrent chemotherapy, and advanced surgical techniques, distant metastasis has become a larger percentage of failures in patients with oral cancer [38] . As a consequence, the survival of patients with HNSCC remained largely unchanged over the last 35 years [39] . The poor survival and high recurrence/metastasis rates in patients with HNSCC can possibly be explained by the CSC hypothesis where the regeneration of a tumor (or the establishment of metastatic foci) requires at least one CSC. Notably, CSC are believed to be resistant to conventional chemotherapeutic drugs, exhibit an invasive phenotype, and resist anoikis or death by anchorage independence. These characteristics make CSC prime candidates to drive the process of recurrence and metastasis frequently observed in patients with head and neck cancer. Here, we performed a series of complementary studies to understand mechanisms used by primary human head and neck CSC to survive while retaining an undifferentiated and highly tumorigenic phenotype.
We have previously demonstrated that the combination of high ALDH activity and high CD44 expression discriminates a small subpopulation of highly tumorigenic cells that have the features of CSC in HNSCC [8] . We found that these cells exist in perivascular niches and that endothelial cell-secreted factors enhanced the survival of the CSC, but the critical mediators of this crosstalk were unclear. The importance of stromal IL-6 on tumor initiation and tumor growth was demonstrated in this study by experiments with xenografts generated with stem-like cells sorted from primary human HNSCC and implanted in immunodeficient IL-62/2 or IL-61/1 mice. We observed a 10-fold decrease in the proportion of cancer stem-like cells in tumors generated in the IL-62/2 mice. These results demonstrated that host-derived IL-6 plays an important role in the survival/self-renewal of CSC. Ongoing studies attempt to determine whether this effect was mediated by a direct interaction of the host IL-6 with the cancer stem-like cells, or indirectly by modulating the inflammatory response. Here, our focus was directed to the endothelial cells as a source of the stromal IL-6 for the following reasons: (a) We observed that endothelial cells express high IL-6 levels in human HNSCC; (b) IL-6 is upregulated under inflammatory conditions [24] , which are typically observed in HNSCC; and (c) CSC exhibit perivascular localization in the head and neck tumor microenvironment.
We observed that endothelial-secreted IL-6 enhances the survival and the stem cell properties of head and neck cancer cells. Interestingly, IL-6 is secreted from thymic blood vessels in response to therapy and promotes the survival of doxorubicin-resistant cells in Burkitt's lymphoma [40] . One could speculate that these resistant cells exhibit stem-like properties. Furthermore, work in lung carcinomas recently showed that stromal endothelial cells contribute to tumor growth [41] . We observed here that IL-6 secreted by endothelial cells is a potent inducer of the tumor-initiating capacity of head and cancer stem-like cells. These data do not exclude the possibility that other cell types (e.g., myeloid cells) contribute to the overall levels of IL-6 in the tumor microenvironment. However, the experiments in which complementary xenograft tumor models are vascularized with IL-6-silenced endothelial cells (or controls) provide strong evidence that IL-6 secreted by the vascular endothelium is a key determinant of the fraction of CSC and the time-to-palpability of tumors. Taken together, these studies identify endothelial cell-initiated signaling events as important mediators of the tumorigenicity of CSC and suggest that such events may contribute to the development of acquired resistance to therapy.
While the concept of perivascular niche for stem cells has been described several years ago [11, 12] , the understanding of the complex cell-cell interactions within the niche is still emerging. It is known that stem cells reside nearby blood vessels in many tissues, including the bone marrow, brain, and heart [42] . It is also known that endothelial cells in steady state secrete IL-6, and that IL-6 expression can be upregulated by inflammatory cytokines such as IL-1b [43] . These studies suggest that endothelial cell-secreted IL-6 may play a role in the maintenance of the stem cell pool within physiological conditions, and perhaps also during inflammation. In head and neck tumors, we observed that IL-6 secreted by endothelial cells induces survival and self-renewal of ALDH HIGH CD44
HIGH cancer stem-like cells. Although we observed an increase in the number of orospheres with rhIL-6 treatment, it was not as potent as the induction mediated by complete endothelial cell CM. This suggests that other endothelial cell-secreted factors might contribute to the biology and behavior of CSC. For example, interleukin-8 (CXCL8) is a chemokine that signals through CXCR1 and CXCR2, is expressed in head and neck cancer, and has been implicated in processes that regulate the biology of CSC [44] [45] [46] . We have also recently observed that endothelial cell-secreted epidermal growth factor induces epithelial to mesenchymal transition (EMT) in head and neck cancer cells, enhancing their 2854 Endothelial IL-6 and Cancer Stem Cells V C AlphaMed Press 2014 migratory and invasive phenotype [47] . It is certainly possible that complex signaling networks are activated by multiple cytokines and chemokines secreted by endothelial cells, which would explain the preferential localization of CSC in perivascular areas.
Our in vitro results demonstrated that the invasive potential of head and neck CSC is enhanced by the growth factor milieu secreted by endothelial cells in an IL-6-dependent manner. Such findings suggest that IL-6 secreted by endothelial cells could facilitate the initiation of the metastatic spread by generating a chemotactic gradient that attracts tumor cells toward blood vessels. In fact, a recent study showed that targeting STAT3 with Cucurbitacin I inhibited tumorigenicity and distant metastasis in head and neck tumor models [20] . This suggests a role of IL-6/STAT3 signaling in EMT of HNSCC, as seen in breast cancers [48] . Likewise, local secretion of IL-6 at sites of endothelial cell inflammation or injury might facilitate the homing of circulating tumor progenitor cells to specific sites or organs, and contribute to the development of distant metastases. Although the mechanisms underlying the effect of stem cells on the biology of HNSCC are still unclear, our data suggest that a crosstalk initiated by endothelial cells contributes to the progression of head and neck tumors and that interference with this crosstalk may constitute a viable conceptual target for treatment of these tumors.
Collectively, the understanding of the physiological role of IL-6 and the mechanistic studies performed here, provided the rationale for the therapeutic targeting of the IL-6 signaling pathway in HNSCC. It has been observed that the most common adverse effects of therapeutic inhibition of IL-6R in clinical studies are respiratory tract infections, headaches, and hypertension [49] , which might be related to biological roles of endothelial cell-derived IL-6 in the recruitment of immune cells and regulation of vascular physiology. Furthermore, IL-6 inhibitors are currently being tested in clinical trials for cancer apart from their use in chronic inflammatory conditions. For example, the anti-IL-6 monoclonal antibody CNTO 328 (siltuximab) is in clinical trials for refractory multiple myelomas and metastatic renal cell cancer [50, 51] . Blockade of IL-6R signaling with tocilizumab inhibited xenograft tumor angiogenesis [27] . Here, we observed that tocilizumab dramatically inhibited the tumor-initiating capacity of primary human cancer stem-like cells. Notably, the fraction of cancer stem-like cells was significantly decreased in the mice treated with tocilizumab suggesting that inhibition of IL-6R signaling was sufficient to reduce the survival and/or self-renewal of head and neck cancer stem-like cells in vivo.
CONCLUSIONS
We have recently demonstrated that silencing of IL-6 in endothelial cells is sufficient to slowdown tumor growth in proofof-principle experiments using a cervical adenocarcinoma model [52] . Here, we demonstrated that endothelial cellsecreted-IL-6 signaling through IL-6R promotes self-renewal and survival of human primary head and neck cancer stemlike cells (Fig. 6) . Blockade of this signaling pathway inhibited tumor initiation and reduced the fraction of cancer stem-like cells in existing tumors. This work establishes the crosstalk between endothelial cells and putative CSC as a critical mechanism of tumor initiation, and singles out IL-6 as an important signaling molecule in this process. Considering the fact that endothelial cells are readily accessible to systemic therapies, and the recent discovery of potent and specific inhibitors, therapeutic targeting of the IL-6 signaling pathway is emerging as a promising therapeutic strategy for patients with head and neck squamous cell carcinoma.
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